FIRST-IN-CLASS DRUG CANDIDATES

With dermatology, oncology, anti-inflammatory, and antibiotic applications

HELPING PATIENTS ACHIEVE CLEARER SKIN

Prurisol—a promising new dermatology treatment for psoriasis

TARGETING p53 TO DEFEAT CANCER

Kevetrin—a potential breakthrough in the field of oncology

LEVERAGING THE BODY’S NATURAL DEFENSE

Brilacidin—the first in a novel class of immunomodulatory drugs

PRURISOL

Oral psoriasis drug candidate in a Phase 2b trial utilizing the advantages of 505(b)(2) development approach

KEVETRIN

Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer

Member of a new antibiotic class with unique immunomodulatory properties granted Fast Track designations